SERB Pharmaceuticals nelle notizie
Fornitore globale di medicinali rari
Tamtam ha trovato 17 articoli recenti su SERB Pharmaceuticals.
- SERB Applauds Publication of Consensus Statements and Recommendations for Neuroblastoma Care in Pediatric Blood & Cancer
- Hansa Biopharma announces closing of €115 million licensing transaction with SERB Pharmaceuticals for Idefirix in Europe and MENA
- SERB Sizes Up €1bn Sales With M&A Savoir Faire
- Hansa licenses Idefirix to SERB for $133m
- Mayer Brown advises SERB Pharmaceuticals on the agreement entered into with Hansa Biopharma AB to acquire European and MENA rights to Idefirix®(imlifidase)
- Hansa Biopharma licenses IDEFIRIX to SERB Pharmaceuticals in €115 million deal
- Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
- SERB signs agreement to acquire Idefirix rights for $133.6m
- SERB Pharmaceuticals buys European and MENA rights to kidney transplant drug Idefirix for €115M
- SERB Pharmaceuticals to acquire European and MENA rights to Idefirix® (imlifidase) from Hansa Biopharma for €115 million
- Hansa Biopharma Signs €115 Million Imlifidase Licensing Agreement with SERB
- SERB to pay Hansa €110M upfront for EU rights to kidney transplant drug
- SERB Pharma to acquire European and MENA rights to Idefirix from Hansa
- SERB Pharmaceuticals Announces ThyroSafe 130 mg Potassium Iodide Tablets are Now Commercially Available in the US
- Dr Vignesh Rajah
- SERB Pharmaceuticals to Acquire Y-mAbs Therapeutics for $412 Million
- Y-Mabs falls to Serb | ApexOnco - Clinical Trials news and analysis
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come SERB Pharmaceuticals?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili